Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

M.D. Anderson Cancer Center

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: Ductal Lavage Fluid Collection

Study type: Observational

Funder types: Other

Identifiers

NCT01207635

LAB02-0400

Details and patient eligibility

About

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.

Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

Enrollment: 42 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient must have a history of breast cancer.
• Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
• Patient must be willing to undergo a duct lavage.
• Patient must sign an Informed Consent.

Exclusion criteria

• None.

Trial design

42 participants in 1 patient group

Breast Cancer Patients

Treatment:

Procedure: Ductal Lavage Fluid Collection